Comparison of Outcomes in Bowel Resections by Gynecologic Oncologists Versus General Surgeons During Maximal Cytoreductive Surgery for Advanced Ovarian Cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3006).
Bowel resection
Cytoreductive surgery
Gynecologic oncologist
Low anterior resection
Maximal cytoreductive surgery
Ovarian cancer
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
received:
11
03
2024
accepted:
06
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
This report describes the oncologic outcomes for patients with advanced ovarian cancer who had bowel surgery performed by gynecologic oncologists (GOs) and compares the outcomes with those for bowel surgery performed by general surgeons (GSs) during maximal cytoreductive surgery. Patients from six academic institutions who had FIGO stage III or IV ovarian cancer and underwent any bowel surgeries during maximal cytoreductive surgery were eligible for the study. The patients were divided into two groups according to whether bowel surgery was performed by a GO or a GS. In both groups, the GOs were mainly involved in extra bowel debulking procedures. Perioperative and survival outcomes were compared between the two groups. The 761 patients in this study included 113 patients who underwent bowel surgery by a GO and 648 who had bowel surgery by a GS. No discernible differences were observed in age, American Society of Anesthesiology (ASA) score, FIGO stage, histologic type, timing of cytoreductive surgery (primary or interval debulking surgery), or complications between the two groups. The GO group exhibited a shorter operation time than the GS group. Kaplan-Meier analysis showed no survival differences between the two groups. In the Cox analysis, non-serous cell types and gross residual diseases were associated with adverse effects on overall survival. However, performance of bowel surgery by a GO did not have an impact on survival. Performance of bowel surgery by a GO during maximal cytoreductive surgery is both feasible and safe. These results should be reflected in the training system for GOs regarding bowel surgery, and further research is needed to confirm that GOs can play a more leading role in performing extra-uterine procedures.
Sections du résumé
BACKGROUND
BACKGROUND
This report describes the oncologic outcomes for patients with advanced ovarian cancer who had bowel surgery performed by gynecologic oncologists (GOs) and compares the outcomes with those for bowel surgery performed by general surgeons (GSs) during maximal cytoreductive surgery.
METHODS
METHODS
Patients from six academic institutions who had FIGO stage III or IV ovarian cancer and underwent any bowel surgeries during maximal cytoreductive surgery were eligible for the study. The patients were divided into two groups according to whether bowel surgery was performed by a GO or a GS. In both groups, the GOs were mainly involved in extra bowel debulking procedures. Perioperative and survival outcomes were compared between the two groups.
RESULTS
RESULTS
The 761 patients in this study included 113 patients who underwent bowel surgery by a GO and 648 who had bowel surgery by a GS. No discernible differences were observed in age, American Society of Anesthesiology (ASA) score, FIGO stage, histologic type, timing of cytoreductive surgery (primary or interval debulking surgery), or complications between the two groups. The GO group exhibited a shorter operation time than the GS group. Kaplan-Meier analysis showed no survival differences between the two groups. In the Cox analysis, non-serous cell types and gross residual diseases were associated with adverse effects on overall survival. However, performance of bowel surgery by a GO did not have an impact on survival.
CONCLUSION
CONCLUSIONS
Performance of bowel surgery by a GO during maximal cytoreductive surgery is both feasible and safe. These results should be reflected in the training system for GOs regarding bowel surgery, and further research is needed to confirm that GOs can play a more leading role in performing extra-uterine procedures.
Identifiants
pubmed: 38961041
doi: 10.1245/s10434-024-15643-9
pii: 10.1245/s10434-024-15643-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015;26:336–42.
doi: 10.3802/jgo.2015.26.4.336
pubmed: 26197773
pmcid: 4620371
Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130:493–8.
doi: 10.1016/j.ygyno.2013.05.040
pubmed: 23747291
Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.
doi: 10.1006/gyno.1998.4955
pubmed: 9600815
Dottino JA, He W, Sun CC, et al. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020;30:1195–202.
doi: 10.1136/ijgc-2020-001243
pubmed: 32616627
pmcid: 8328049
Ye S, Wang Y, Chen L, Wu X, Yang H, Xiang L. The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. BMC Surg. 2022;22:81.
doi: 10.1186/s12893-022-01531-0
pubmed: 35246104
pmcid: 8895854
Searle G, Pounds R, Phillips A, et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis. Gynecol Oncol. 2020;158:54–8.
doi: 10.1016/j.ygyno.2020.04.048
pubmed: 32345546
Arora V, Somashekhar SP. Essential surgical skills for a gynecologic oncologist. Int J Gynecol Obstet. 2018;143:118–30.
doi: 10.1002/ijgo.12619
Nishikimi K, Tate S, Kato K, Matsuoka A, Shozu M. Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely. J Gynecol Oncol. 2020;31(1):e3.
doi: 10.3802/jgo.2020.31.e3
pubmed: 31788993
Subspecialist guideline for gynecologic oncologist of Korean Society of Gynecologic Oncology. KSGO
Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.
doi: 10.1016/j.ajog.2007.10.495
Tozzi R, Valenti G, Vinti D, Campanile RG, Cristaldi M, Ferrari F. Rectosigmoid resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team. J Gynecol Oncol. 2021;32:e42.
doi: 10.3802/jgo.2021.32.e42
pubmed: 33825357
pmcid: 8039168
Lim MC, Won YJ, Ko MJ, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015. J Gynecol Oncol. 2019;30:e38.
doi: 10.3802/jgo.2019.30.e38
pubmed: 30574686
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.
doi: 10.1200/JCO.2002.20.5.1248
pubmed: 11870167
Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011:Cd007697.
Mulligan K, Corry E, Donohoe F, et al. Multidisciplinary surgical approach to increase survival for advanced ovarian cancer in a tertiary gynaecological oncology centre. Ann Surg Oncol. 2024;31:460–72.
doi: 10.1245/s10434-023-14423-1
pubmed: 37875740
Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol. 2001;82:489–97.
doi: 10.1006/gyno.2001.6312
pubmed: 11520145
Tewari KS. Advanced cytoreductive surgery workshop report. Int J Gynecol Cancer. 2012;22:1604–10.
doi: 10.1097/IGC.0b013e3182738338
pubmed: 23095776
Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203–9.
doi: 10.1016/0090-8258(92)90107-T
pubmed: 1468698
Huddart D, Rajkumar S, Kolomainen D, Mehra G, Nath R, Sayasneh A. Gynae-oncology surgeons’ preparedness to undertake colorectal procedures during cytoreductive surgery for ovarian cancer: a cross sectional survey. J Clin Med. 2022;11(21):6233.
Son JH, Kim J, Shim J, et al. Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: close rectal dissection versus total mesorectal excision. Gynecol Oncol. 2019;153:362–7.
doi: 10.1016/j.ygyno.2019.02.029
pubmed: 30846223
Derlatka P, Sienko J, Grabowska-Derlatka L, et al. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol. 2016;14:58.
doi: 10.1186/s12957-016-0800-1
pubmed: 26923029
pmcid: 4770554
Obermair A, Hagenauer S, Tamandl D, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83:115–20.
doi: 10.1006/gyno.2001.6353
pubmed: 11585422